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W. Duncan Reekie, M. J. Buxton
This paper applies cost-effectiveness analysis to a major
clinical innovation. Using a structured survey of
professional judgements to obtain estimates of research
costs associated with its use, the analysis suggests that a
premium price for the drug decided on by the
manufacturer would be justified on the grounds that it
could provide substantial cost savings. The results
obtained appeared sensitive neither to variations in the
cost assumptions, nor to alternative definitions of
effectiveness. In general, ex ante economic evaluation of a
new medicine before price setting is shown to be both
feasible and informative.
S Afr Med J 1994; 84: 421-423.
Earlier research examined pharmaceutical innovations in
aggregate and showed how prices reflect market conditions
such as innovation 'quality', potential entry and price elasti-
city.''> Subsequently, individual product studies used
techniques of cost-benefit analysis.'" These studies were ex
post in that the products had already been marketed at
particular prices. More recently, in an ex ante study, Buxton
.and O'Brien5 applied cost-effectiveness analysis to a still-to-
be-launched new pharmaceutical product the price of which
had yet to be set, but for which clinical data on
effectiveness were available. This paper builds on that study
using improved cost data. Buxton and O'Brien5used 'crude
estimates' of costs. In this study representative costs were
obtained empirically from structured sample surveys of
clinical and administrative experts.
The paper examines how cost-effectiveness analysis can
be used to guide pricing decisions. In particular it addresses
the case of ondansetron, a newly available anti-emetic drug
explicitly designed for use by patients undergoing chemo- or
radiotherapy.
Clinical trial data" available prior to the pricing decision,
comparing the anti-emetic properties of intravenous
ondansetron with the previous drug of choice,
metoclopramide, suggest that cancer patients receiving
cisplatin chemotherapy plus ondansetron are less likely to
suffer from both significant emesis and significant side-
effects. How can clinical superiority justifiably be reflected in
corporate pricing policy, given the background of a health
care delivery system under constant pressure to contain
costs? This is the issue that this paper addresses.
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Cost minimisation and cost-
effectiveness
Optimal cost-containment may not necessarily imply cost
minimisation. Cost-minimisation analysis compares two or
more alternative courses of action, e.g. of medical treatment,
and assumes they are either identical, or sufficiently similar
for any differences to be ignored. Cost-effectiveness
analysis, however, compares the costs to the level of
outcome achieved by different methods. Thus if two anti-
emetics can be used in chemotherapy but one is more





The data used in this paper come from two sources. Clinical
trial results were obtained from a British study." A multi-
centre double-blind crossover trial was carried out to
compare the efficacy and safety of ondansetron with those
of metoclopramide in the prophylaxis of acute nausea and
vomiting induced by cisplatln-containing cancer chemo-
therapy regimens. The researchers used a randomised
crossover design with two treatment periods 3-4 weeks
apart. Details of the alternative regimens applied over the
24-hour period are given in the questionnaire (available from
the authors): The two subsamples, aged 29-69 years, were
hospitalised and had a variety of primary tumour locations.
The data used related primarily to three variables: (I) the
presence or absence of significant emesis; IJI) the presence
or absence of significant side-effects; and (iil) whether these
side-effects were resolved. Definitions used in the trial for
these terms are given in the questionnaire. The second set
of data was economic not clinical. The clinical results can
reasonably be presumed to be internationally transferable.
Buxton and O'Brien's5 cost estimates can be improved upon,
however. Their study used 'crude estimates', not actual
costs incurred. Furthermore, patterns of treatment and the
mix of medical personnel employed vary between and also
within countries, while the relative cost structures of
hospitals are not homogeneous. This study collected actual
local cost data and applied them to the clinical evidence.
Two panels of South African clinical experts were
established, one 'coastal' and one 'inland', drawn from
different oncological centres throughout the country. The
former met in Cape Town and the latter in Johannesburg.
Each panel comprised an oncologist, an oncological nursing
sister, a hospital pharmacist, a member of the South African
Cancer Association and a senior hospital administrator. The
cost data obtained thus spanned not only the regional divide
but also the wide institutional differences between teaching
hospitals, private clinics, large provincial hospitals and small
town units.
Main analysis
Fig. 1 summarises the outcome of the clinical trial results in
a schematic format common in the literature of clinical
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Additional cost of dealing with side-effects (R)
(per patient with significant side-effects)
10,5 minutes of nursing time
Probability cost of additional day's hospitalisation
Total
Additional cost of dealing with emesis (R)
(per patient with significant emesis)
24 minutes of nursing time
Linen, disposables, etc.
Probability cost of additional day's hospitalisation
Total
Table I. Cost estimates
Additional cost of treating side-effects (R)
(per patient who received treatment)




From these cost-estimates, and the known probabilities of
the events in the pathways, the final column of Fig. 1 was
computed, the total of which gives the expected or average
total incremental direct cost of treating any given patient
with each product: namely R172,90 for metoclopramide and
R83,03 for ondansetron. If we now add the respective prices
for each product we have:
Ondansetron
Price R225,00
Incremental cost R 83,03
R308,03
At this point we have effectively undertaken a cost-
minimisation exercise which indicates that metoclopramide
is the product of choice. However, had ondansetron been
priced at R137,87, nearly three times the metoclopramide
level, then it would have been the least costly product (see
Appendix).
Cost-effectiveness analysis takes account of therapeutic
differences in success. If 'success' is defined as no
significant emesis, the ondansetron offers a 0,75 chance
of success as against metoclopramide's 0,42 probability
(Fig. 1). If 'success' entails an absence of side-effects, the
respective probabilities are given in pathways 6 of Fig. 1.
Ondansetron's success rate is 0,67 (0,75 x 0,89) as against
metoclopramide's 0,37 (0,42 x 0,88); Le. if 100 patients were
treated with ondansetron, 67 would be successfully treated
as against 37/100 patients on a metoclopramide regimen.
The expected total expenditures on the respective groups
of 100 patients would be R30 803 with ondansetron and
R22 090 with metoclopramide. If these measures of
differential effectiveness are taken into account then the
following applies:
Effective cost per 'successfully' treated patient:
('success' = no emesis)
The 'average' or 'expected' figures given above were computed from worst case'. 'best
case' and 'most likely case' answers to the questionnaire. The computation was as
follows:
best case + (4 x most likely case) + worst case
Expected value = 6
where 'expected' value is the calculated mean of a beta distribution, given that'besf and
'worsf are the extreme values and 'most likely' the modal value of that distribution.
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decision analysis."· The outcome probabilities were derived
directly from the original trial data." The patients were divided
into two mutually exclusive groups each of which had ten
mutually exclusive possible outcomes or pathways (P1 to
P10). For example, of the patients treated with ondansetron
75% suffered no significant emesis. Of this 75% a subset of
11 % suffered significant side-effects, of which 17% were
treated; 100% of those treated had the side-effects resolved.
The next step in the analysis was to compute the full
usage costs of both ondansetron and metoclopramide. Full
usage costs in the case of anti-emetics encompass the
costs of dealing with the residual emesis and of coping with
side-effects, other than emesis, of the treatment (whether
caused by the anti-emetic or.the chemotherapy). The direct
price difference between metoclopramide therapy and
ondansetron was obtained by using the manufacturers'
selling price for the former and the price already set in the
UK market for the latter, Le. R48 for metoclopramide and
R225 (£45) for ondansetron.
Fig. 1 also shows the total incremental costs of each
pathway (Le. exclusive of the prices of each product). These
costs were obtained from the interview panels and represent
the averages of the answers obtained. Table I provides the
three cost-estimates used in the penultimate column of
Fig. 1. Thus the pathway P2 has an incremental cost of
R200 (the cost of dealing with emesis) + R217,87 (the cost
of dealing with side-effects) + R20,62 (the cost of treating
the side-effects) = R438,48.
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Table 11. Cost-effectiveness calculations
Sensitivity analysis
Metoclopramide R220,90 .;. 0,42 = R523,80
Ondansetron R308,03.;. 0,75 =R410,67
('success' = no emesis and no side-effects)
Metoclopramide R220,90 .;. 0,37 = R597,03
Ondansetron R308,03 .;. 0,67 =R459,75
Irrespective of which measure of success is used,
ondansetron is substantially more cost-effective than
metoclopramide when its price is related both to its
differential effectiveness and to its differential net treatment
costs.
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Cost-effectiveness analysis has limitations. Firstly, only
success is valued. It is given a weighting of 1 against a °
weighting for failure. Ideally, the relative utility from the
patients' viewpoint of each of the different endpoints should
be assessed. Secondly, the panels of experts
overwhelmingly agreed that patient morale and quality of life
were the main advantages of success. These certainly result
in cost savings, but the panels may have underestimated the
benefits. It is clear that a premium price for ondansetron
therapy over the cost of metoclopramide can be justified.
On the basis of cost-minimisation analysis, net costs would
be equalised with an ondansetron price of R137,87 on base
case event cost assumptions for dealing with emesis, with
side-effects and of treating side-effects. If differential
effectiveness is allowed for in terms of cost per success
(where success equals no significant emesis and no
significant side-effects) a base case price of R317 would
equalise cost-effectiveness (see Appendix). With a range of
alternative event costs, at a price of R225 ondansetron is
consistently more cost-effective.
Appendix
This paper took the UK price as its benchmark. If no
benchmark price is available but a price is sought which
equalises net costs on a cost-minimising or cost-
effectiveness basis then the following formulae developed
by Buxton and O'Brien should be adopted:
let Co = Cm' (1)
or cjeo = c,,/em (2)
where c and e are cost and effectiveness and the subscripts
denote ondansetron and metoclopramide.
If Co = Po + c1 0 •••• (3)
and Cm = Pm + c1 m.... (4)
where the prime signs indicate the expected costs of emesis
management (from Fig. 1); and if Pm =R48 then by
substitution and rearrangement Po =R137,87, the price
which equalises Co and Cm'
To find Po where equation (2) is satisfied take em and eo
from the probability values of pathways (6) in Fig. 1. Thus:
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What would be the effect if, instead of using data relating to
average nursing costs, doctor costs and hospitalisation
costs, etc., we used cost figures 25% higher or costs 25%
lower than those uncovered in our survey? In short, are the
analyses and the results sensitive to reasonable changes in
the underlying data or not? Table 11 summarises the
calculation done to answer this question. The effect of using
the alternative definition of success is negligible. In each of
the three cases (base case, incremental costs 25% higher
and 25% lower than base) ondansetron at a price of
R225/day is more cost-effective than metoclopramide at
R48/day.
The methodology assumes that the resources not used by
the more cost-effective product will either be 'saved' or put
to use elsewhere. In most cases this will be so. In the
private health care sector medical aid expenditures will be
lower per successful case treated while in the state sector
provincial authorities or teaching hospitals with fixed
resources will be able to use them for other patients and/or
other ailments. Only if resources are highly idiosyncratic and
not transferable does this assumption not hold. These
circumstances are rare and not within the bounds of this
discussion. A clinical analysis and not merely a cost-
sensitivity one could also have been carried out. In other
words, what would have been the impact of differing
pathway probabilities? We are not qualified to suggest what
parameter variations would be realistic. Even so, it must be
borne in mind that our results relate to one particular clinical
trial only and that that clinical result will also be stochastic
not deterministic.
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